<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033081</url>
  </required_header>
  <id_info>
    <org_study_id>CT007</org_study_id>
    <nct_id>NCT04033081</nct_id>
  </id_info>
  <brief_title>Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®</brief_title>
  <official_title>Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CivaTech Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TAB Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CivaTech Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This patient study will determine the safety and toxicity of a permanently implantable
      brachytherapy source - CivaSheet® - which is designed to deliver a therapeutic dose of low
      dose rate (LDR) radiation with polymer encased Palladium-103. CivaSheet will be implanted in
      sarcoma patients with disease presenting in the retroperitoneum, abdomen, pelvis and trunk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CivaSheet® is an FDA-cleared product from CivaTech Oncology®. It is a series of small
      radioactive palladium-103 (Pd-103) sources on bio-absorbable, flexible, bio-compatible
      membrane. The CivaSheet can be custom cut in the operating room. The CivaSheet is 5 cm wide
      by 15 cm long and has a rim to allow an easy surface to suture. This flexible device can
      contour the surgical cavity delivering highly conformal and targeted radiation dose.
      CivaSheet can deliver a very high radiation dose to the surgical margin to potential prevent
      local cancer recurrence.

      Sarcoma patients have up to 80% local recurrence rates, depending on histology and location
      of disease presentation. CivaSheet will be implanted at the surgical margin follow tumor
      removal. Monitoring the rate of acute toxicity is the primary endpoint. Secondary endpoints
      include disease progression and recurrence rates.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of acute toxicity</measure>
    <time_frame>90 days post implant</time_frame>
    <description>rate of greater than or equal to Grade 3 toxicity events based on CTCAE criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>5 years</time_frame>
    <description>rate of local tumor recurrences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation rate</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of re-operation for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of complications following device implant related or unrelated to the device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose to target and OAR</measure>
    <time_frame>90 days</time_frame>
    <description>Amount of radiation dose delivered to the target volume and the adjacent organs at risk</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>CivaSheet Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implanted with CivaSheet during tumor removal</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CivaSheet</intervention_name>
    <description>Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence</description>
    <arm_group_label>CivaSheet Treatment</arm_group_label>
    <other_name>brachytherapy</other_name>
    <other_name>Intraoperative Radiation Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject Signed Inform Consent

          2. Subject plans to remain in the long-term care of his/her enrolling
             center/investigators.

          3. Sarcoma evident on imaging. Pathology biopsy proven or suspected by imaging but not a
             biopsy candidate.

          4. Sarcoma in the retroperitoneum, abdomen, pelvis, or trunk

          5. Subject is able to undergo surgery

        Exclusion Criteria:

          1. Is unable or unwilling to comply with protocol requirements.

          2. Is enrolled in another study/registry not approved by CivaTech Oncology.

          3. Pregnancy, breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krisha Howell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dian Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carra Castagnero</last_name>
    <phone>9193145515</phone>
    <email>clinical@civatechoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristy Perez, PhD</last_name>
    <phone>9193145515</phone>
    <email>clinical@civatechoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rush University Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riley Sticca</last_name>
      <phone>312-563-5769</phone>
      <email>riley_j_sticca@Rush.edu</email>
    </contact>
    <investigator>
      <last_name>Dian Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara McCarney, BSN</last_name>
      <phone>215-728-3512</phone>
      <email>sara.mccarney@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Krisha Howell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CivaSheet</keyword>
  <keyword>IORT</keyword>
  <keyword>Intraoperative Radiation Therapy</keyword>
  <keyword>Brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

